Takuya Iwamoto1, Hiroko Sugimoto2, Tsutomu Tabata3, Masahiro Okuda2. 1. Department of Pharmacy, Mie University Hospital, Tsu, Mie, Japan. Electronic address: taku-iwa@clin.medic.mie-u.ac.jp. 2. Department of Pharmacy, Mie University Hospital, Tsu, Mie, Japan. 3. Departments of Obstetrics and Gynecology, Mie University Graduate School of Medicine, Tsu, Mie, Japan.
Abstract
PURPOSE: Drug desensitization has been found to be an effective option for carboplatin rechallenge in patients at risk for severe hypersensitivity reaction. However, identifying such patients requires precise clinical tests. This study was performed to evaluate the clinical utility of basophil CD203c to predict the timing of carboplatin-induced severe hypersensitivity reaction. METHODS: Here we report on 3 patients undergoing a carboplatin-desensitization protocol at Mie University Hospital. For all patients, ex vivo exposure to carboplatin resulted in increased levels of activated basophils in a previous occurrence of carboplatin-induced severe hypersensitivity reaction. FINDINGS: Basophil activation test using carboplatin was returned to negative just before the first course of carboplatin-desensitization protocol in all patients, and they successfully received their first course of the protocol with no signs of anaphylaxis. However, for all of the patients, increased basophil activation was once again detected after subsequent readministration of carboplatin and grade 3 or 4 anaphylaxis developed. Basophil activation test coincided precisely with the timing of carboplatin-induced anaphylaxis in all patients. IMPLICATIONS: CD203c basophil activation testing might prove to be a reliable tool for risk stratification and clinical decision making for carboplatin desensitization in which severe hypersensitivity reaction is likely to occur.
PURPOSE: Drug desensitization has been found to be an effective option for carboplatin rechallenge in patients at risk for severe hypersensitivity reaction. However, identifying such patients requires precise clinical tests. This study was performed to evaluate the clinical utility of basophil CD203c to predict the timing of carboplatin-induced severe hypersensitivity reaction. METHODS: Here we report on 3 patients undergoing a carboplatin-desensitization protocol at Mie University Hospital. For all patients, ex vivo exposure to carboplatin resulted in increased levels of activated basophils in a previous occurrence of carboplatin-induced severe hypersensitivity reaction. FINDINGS: Basophil activation test using carboplatin was returned to negative just before the first course of carboplatin-desensitization protocol in all patients, and they successfully received their first course of the protocol with no signs of anaphylaxis. However, for all of the patients, increased basophil activation was once again detected after subsequent readministration of carboplatin and grade 3 or 4 anaphylaxis developed. Basophil activation test coincided precisely with the timing of carboplatin-induced anaphylaxis in all patients. IMPLICATIONS: CD203c basophil activation testing might prove to be a reliable tool for risk stratification and clinical decision making for carboplatin desensitization in which severe hypersensitivity reaction is likely to occur.
Authors: Jitesh Chauhan; Alex J McCraw; Mano Nakamura; Gabriel Osborn; Heng Sheng Sow; Vivienne F Cox; Chara Stavraka; Debra H Josephs; James F Spicer; Sophia N Karagiannis; Heather J Bax Journal: Antibodies (Basel) Date: 2020-10-16
Authors: Jitesh Chauhan; Chara Stavraka; Melanie Grandits; Lais C G F Palhares; Debra H Josephs; Katie E Lacy; James Spicer; Heather J Bax; Sophia N Karagiannis Journal: Cells Date: 2022-01-27 Impact factor: 7.666
Authors: Heather J Bax; Jitesh Chauhan; Chara Stavraka; Atousa Khiabany; Mano Nakamura; Giulia Pellizzari; Kristina M Ilieva; Sara Lombardi; Hannah J Gould; Christopher J Corrigan; Stephen J Till; Sidath Katugampola; Paul S Jones; Claire Barton; Anna Winship; Sharmistha Ghosh; Ana Montes; Debra H Josephs; James F Spicer; Sophia N Karagiannis Journal: Cells Date: 2020-07-07 Impact factor: 6.600